Kezar Shifts Focus From Tumor Drug to Autoimmune Therapy
Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
- Latest
- Trending
Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Alignment Healthcare, Inc. (ALHC) is a Medicare advantage company with revenue growth of 28.6%. Stock price at $5.02, analysts recommend ...
Dyne Therapeutics appoints new CEO, George Eliades, and other key executives as it prepares for growth. Robert Coffin to step ...
Adial Pharmaceuticals, Inc. - A biopharmaceutical company focusing on addiction therapeutics. Stock faced challenges this year, with price drops. Leadership ...
Discover the financial report of Theratechnologies Inc., a biopharmaceutical company specializing in healthcare therapies. Learn about their market cap, leadership ...
Diversity in biotechnology and venture capital is crucial for driving innovation and breakthroughs in healthcare, according to Dr. Stanley Lewis. ...
Efforts to diversify biotech venture capital funding could lead to innovation, breakthroughs in healthcare, and improved outcomes for minorities.
Otsuka's phase 3 trial for AVP-786 in treating agitation in Alzheimer's patients has failed to meet the primary efficacy endpoint. ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.